EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

NCT07410676 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

83

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Sarcoma
Leukaemia
Breast Cancer (Locally Advanced or Metastatic)
Lung Cancer (Diagnosis)
Colorectal Cancer
Melanoma (Skin Cancer)
Bladder Cancer
Kidney Cancer
Pancreatic Cancer Metastatic
Liver Cancer (Primary and Metastatic)
Ovarian Cancer
Esophageal Cancer
Glioblastoma
Non-Melanoma Skin Cancer

Interventions

BIOLOGICAL: EBNK-001 + IL-15 + Pembrolizumab

Sponsor

Essen Biotech